Evista (raloxifene) Disease Interactions
There are 2 disease interactions with Evista (raloxifene):
Raloxifene (Includes Evista) ↔ Thromboembolism
Severe Potential Hazard, High plausibility
Applies to: Thrombotic/Thromboembolic Disorder, History - Thrombotic/Thromboembolic Disorder, Congestive Heart Failure
The use of raloxifene is contraindicated in patients with active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis. In clinical trials, women treated with raloxifene had an increased risk of venous thromboembolism. A less serious event, superficial thrombophlebitis, also has been reported more frequently with raloxifene. The greatest risk for deep vein thrombosis and pulmonary embolism occurs during the first four months of treatment. Therapy with raloxifene should be considered cautiously in women at risk for thromboembolic disease for other reasons, such as congestive heart failure, superficial thrombophlebitis, and active malignancy.
Raloxifene (Includes Evista) ↔ Liver Disease
Moderate Potential Hazard, Moderate plausibility
Applies to: Liver Disease
Raloxifene undergoes extensive first-pass metabolism in the liver. Following administration of a single oral dose in Child-Pugh Class A patients with cirrhosis and total serum bilirubin ranging from 0.6 to 2.0 mg/dL, plasma raloxifene concentrations were 2.5 times higher than in controls. Therapy with raloxifene should be administered cautiously in patients with hepatic insufficiency, since safety and efficacy have not been evaluated. Although raloxifene is generally well tolerated, even at dosages higher than currently recommended, patients with liver disease should be monitored for occurrence of undue adverse effects during raloxifene therapy.
You should also know about...
Evista (raloxifene) drug Interactions
There are 48 drug interactions with Evista (raloxifene)
See also...
Drug Interaction Classification
The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
